Biosimilar medicines: creating sustainable competition in an era of a new patent cliff in biological medicines

Abstract

For many years European governments have sought to ensure a high degree of competition in off-patent pharmaceutical markets in order to generate price competition and consequently benefits such as improved patient access or savings for payers after patent expiry. The pharmaceutical industry believes that access to valuable new treatments and post… (More)

Topics

1 Figure or Table

Cite this paper

@inproceedings{Baelen2015BiosimilarMC, title={Biosimilar medicines: creating sustainable competition in an era of a new patent cliff in biological medicines}, author={Maarten Van Baelen}, year={2015} }